Shares of ASLAN PHARMACEU/ADR (NASDAQ:ASLN) were up 9.3% during trading on Friday . The company traded as high as $2.67 and last traded at $2.00, approximately 152,400 shares were traded during trading. An increase of 653% from the average daily volume of 20,249 shares. The stock had previously closed at $1.83.
A number of analysts have commented on ASLN shares. HC Wainwright set a $9.00 target price on shares of ASLAN PHARMACEU/ADR and gave the company a “buy” rating in a report on Wednesday, June 5th. ValuEngine raised shares of ASLAN PHARMACEU/ADR from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research cut shares of ASLAN PHARMACEU/ADR from a “hold” rating to a “sell” rating in a research note on Thursday, August 15th.
The stock’s 50 day moving average price is $2.40 and its 200-day moving average price is $3.37. The company has a quick ratio of 3.80, a current ratio of 2.54 and a debt-to-equity ratio of 0.81. The stock has a market capitalization of $75.96 million, a PE ratio of -1.43 and a beta of 2.37.
An institutional investor recently raised its position in ASLAN PHARMACEU/ADR stock. Platinum Investment Management Ltd. lifted its position in ASLAN PHARMACEU/ADR (NASDAQ:ASLN) by 7.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 415,450 shares of the company’s stock after purchasing an additional 27,055 shares during the period. Platinum Investment Management Ltd. owned about 1.30% of ASLAN PHARMACEU/ADR worth $1,275,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 7.16% of the company’s stock.
ASLAN PHARMACEU/ADR Company Profile (NASDAQ:ASLN)
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
Further Reading: What is the Rule of 72?
Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.